Exchange: NASDAQ·Updated 06:19 AM EDT
CRSP logo

CRSPCRISPR Therapeutics AG

$47.78
$0.79
(1.68%)
Pre-Market
Prev Close $46.99
EarningsAug 10
Mkt Cap$4.61B
Vol2,936.00
News
all
press releases
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Zacks
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
Zacks
News Placeholder
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.
Zacks
News Placeholder
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks
News Placeholder
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
Zacks
News Placeholder
3 Reasons to Buy CRISPR Therapeutics Stock
Key PointsCRISPR Therapeutics is a good pick to ride the gene editing revolution...
Nasdaq News: Markets
News Placeholder
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Zacks
News Placeholder
A New CRISPR 'DNA Shredder' Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Key PointsGene-editing is a handy tool for developing sophisticated medicines...
Nasdaq News: Markets
News Placeholder
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Zacks
News Placeholder
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
Key PointsCRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.